Medicare Part D GLP-1 Coverage Starting July 2026: The Complete Guide to Wegovy and Zepbound at $50/Month

For the first time in Medicare's history, weight loss medications will be covered under Part D. The Medicare GLP-1 Bridge demonstration, announced by CMS on December 23, 2025, launches on July 1, 2026. It covers two FDA-approved GLP-1 medications — Wegovy (semaglutide) and Zepbound (tirzepatide) — for eligible Medicare Part D beneficiaries at a flat $50 per month copay.

This is not a small policy tweak. Approximately 68 million Americans are enrolled in Medicare, and more than two-thirds of Medicare beneficiaries are classified as overweight or obese. CMS estimates roughly 10% of all Medicare beneficiaries — potentially 3.4 million or more people — could qualify for this program in the first six months alone. For a population that has been explicitly locked out of weight loss drug coverage since Medicare Part D began in 2006, this represents a seismic shift.

This guide covers every detail you need: exactly who qualifies, which medications are included, how the prior authorization process works, what happens after the Bridge ends in December 2026, and a month-by-month preparation timeline so you're ready on day one.

What Is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge is a time-limited demonstration program that runs from July 1 through December 31, 2026. It was created to provide immediate access to GLP-1 weight loss medications for Medicare Part D beneficiaries while CMS builds the longer-term BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), which launches for Part D plans in January 2027.

The "bridge" name is literal — it bridges the gap between the announcement of Medicare GLP-1 coverage (December 2025) and the full rollout of the permanent BALANCE program (January 2027). During the bridge period, CMS handles everything centrally rather than routing through individual Part D plans.

The pricing was made possible by a Most-Favored-Nation deal between the Trump administration and both Novo Nordisk (Wegovy) and Eli Lilly (Zepbound). Both manufacturers agreed to a net price of $245 per month — roughly 75-80% below the retail list price. You pay $50 of that, and the program covers the rest.

Which Medications Are Covered?

As of the program launch, three specific products are eligible under the Medicare GLP-1 Bridge when prescribed for weight reduction:

The copay is the same regardless of which product you choose or which dose you're on. Whether you're on a starting dose of Wegovy at 0.25 mg or a full maintenance dose of Zepbound at 15 mg, you pay $50 per month.

If you're not sure which medication is the better fit, our Wegovy vs Zepbound comparison breaks down the clinical trial data, side effect profiles, and dosing differences. The short version: Zepbound produces about 6 percentage points more weight loss at maximum doses (20.2% vs 13.7% in the SURMOUNT-5 head-to-head trial), but Wegovy offers an oral tablet option for people who prefer pills over injections.

Medications NOT covered under the Bridge include Ozempic (semaglutide for diabetes), Mounjaro (tirzepatide for diabetes), Saxenda (liraglutide), and any compounded semaglutide or tirzepatide. The Bridge only covers FDA-approved GLP-1 medications with a specific weight loss indication.

Eligibility: Who Qualifies for the Medicare GLP-1 Bridge?

The eligibility criteria are more specific than many people expect. You must meet ALL of the following baseline requirements plus at least one of the three clinical tiers:

• •Be at least 18 years of age
• •Be actively enrolled in a Medicare Part D prescription drug plan (PDP) or a Medicare Advantage plan with prescription drug coverage (MA-PD) for the 2026 plan year
• •Be prescribed a GLP-1 to reduce excess body weight and maintain weight reduction, in combination with lifestyle modification including structured nutrition and physical activity
• •Meet one of the three BMI-based clinical tiers below

Here are the three clinical eligibility tiers, based on BMI at the time you start GLP-1 therapy:

Notice the tiered structure. The highest BMI threshold (35+) requires no additional diagnoses. The middle tier (30+) requires specific chronic conditions. The lowest threshold (27+) requires serious cardiovascular or metabolic conditions. This is more restrictive than the standard FDA-approved indications for Wegovy and Zepbound, which generally require BMI >= 30 or BMI >= 27 with any weight-related comorbidity.

Not sure if your BMI qualifies? For reference, a 5'4" person weighs approximately 204 lbs at a BMI of 35, 175 lbs at BMI 30, and 157 lbs at BMI 27. A 5'10" person hits those thresholds at roughly 244 lbs, 209 lbs, and 188 lbs respectively.

How the Prior Authorization Process Works

Unlike standard Part D medications, the Medicare GLP-1 Bridge uses a centralized system rather than routing through your individual Part D plan. Here is how the process works step by step:

• •Step 1: See your doctor. Your physician evaluates you, documents your BMI, confirms qualifying conditions, and determines that a GLP-1 medication is clinically appropriate for weight management.
• •Step 2: Provider submits prior authorization. Your doctor submits a prior authorization request to the central processor — NOT to your Part D plan. CMS has designated Humana, which already administers the Limited Income Newly Eligible Transition (LI NET) program, as the central processor for the Bridge.
• •Step 3: Central processor reviews and approves. Humana reviews the PA request against the eligibility criteria. If approved, your doctor receives confirmation and can prescribe the medication.
• •Step 4: Fill at a pharmacy. Take your prescription to a participating pharmacy. The pharmacy uses a specific BIN and PCN (routing numbers) to submit the claim to the central processor, not your Part D plan.
• •Step 5: Pay $50. The pharmacy collects your $50 copay. The pharmacy is reimbursed for the remainder at wholesale acquisition cost minus the copay, plus a dispensing fee.

CMS has stated that more detailed operational guidance — including specific pharmacy BIN/PCN numbers and participating pharmacy lists — will be released in Spring 2026 (likely May or June). We will update this guide when those details are published.

What You Will Actually Pay: Cost Breakdown

The $50/month flat copay sounds straightforward, but there are several cost details worth understanding:

To put the $50/month copay in perspective, here is what these medications cost through other channels:

For the roughly 68 million Medicare beneficiaries who previously had zero coverage for weight loss medications, $50/month represents a transformative reduction. Many seniors have been paying $349-$1,349 per month out of pocket or simply going without. Use our cost calculator to see how the Bridge program compares to other options based on your specific situation.

Preparation Timeline: What to Do From April Through June 2026

You have roughly three months before the July 1 launch. Here is a month-by-month action plan to make sure you can fill a prescription as close to day one as possible:

April 2026: Research and self-assessment

• •Calculate your BMI and determine which eligibility tier you may fall under. Remember: Tier 1 is BMI >= 35 (no additional conditions), Tier 2 is BMI >= 27 with cardiovascular/metabolic conditions, Tier 3 is BMI >= 30 with specific chronic conditions
• •Gather your medical records documenting any qualifying comorbidities (pre-diabetes, history of heart attack or stroke, peripheral artery disease, HFpEF, uncontrolled hypertension on 2+ medications, or CKD stage 3a+)
• •Verify that your Medicare Part D plan is active and current for 2026. If you have a Medicare Advantage plan with drug coverage (MA-PD), confirm it's active
• •Research which GLP-1 medication you're interested in — read our Wegovy vs Zepbound comparison and consider whether you want an injection or the oral Wegovy tablet option
• •Take our GLP-1 provider match quiz to find a telehealth provider that works with Medicare patients, or prepare to discuss GLP-1 options with your existing primary care physician

May 2026: Medical appointments and documentation

• •Schedule an appointment with your doctor specifically to discuss GLP-1 therapy for weight management
• •Have your BMI officially documented in your medical record at the visit — this will be required for prior authorization
• •Ensure any qualifying conditions are documented with appropriate diagnosis codes (ICD-10 codes) in your chart
• •Discuss which medication your doctor recommends based on your health history, other medications, and preferences
• •Ask your doctor if they're prepared to submit prior authorization to the Bridge program's central processor (Humana) starting in late June or early July
• •Watch for CMS announcements about operational details, participating pharmacies, and the PA submission process — expected in Spring 2026

June 2026: Final preparation

• •Confirm with your doctor's office that they have the Bridge program's prior authorization submission process ready (BIN/PCN numbers, submission portal details)
• •Identify a participating pharmacy — CMS should release the pharmacy network details by this point
• •If your doctor plans to prescribe an injectable GLP-1, familiarize yourself with self-injection technique. Our injection tips guide covers the basics
• •Set a calendar reminder for July 1 — ask your doctor to submit the prior authorization as early as the program allows
• •Have a backup plan: if the PA takes time to process, know what your out-of-pocket options are (LillyDirect at $299/mo for Zepbound vials, NovoCare at $349/mo for Wegovy) so you can start treatment while waiting for approval if desired

What Happens After December 2026: The BALANCE Model

The Medicare GLP-1 Bridge is temporary — it ends December 31, 2026. Starting January 1, 2027, GLP-1 coverage for weight loss transitions to the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), a voluntary CMS Innovation Center demonstration.

Here is how BALANCE differs from the Bridge:

The biggest difference is that BALANCE is voluntary for Part D plans. Your plan must choose to participate. If it doesn't, you may need to switch plans during the 2027 Open Enrollment Period (October 15 - December 7, 2026) to a plan that does participate in BALANCE.

BALANCE also adds a mandatory lifestyle support component provided by the drug manufacturers at no cost to you. This will likely include nutrition counseling, physical activity programs, and behavioral health support. CMS has said this reflects emerging evidence that combining GLP-1 medications with lifestyle interventions produces better long-term outcomes than medication alone.

Novo Nordisk has also announced list price cuts of 50-70% for Wegovy, Ozempic, and Rybelsus taking effect in January 2027. This will bring Wegovy's list price down to approximately $675/month — still well above the $245 negotiated Bridge price, but a significant reduction that could improve access across all payer types.

Frequently Asked Questions

Can I use the Bridge program if I already have GLP-1 coverage through my Part D plan for diabetes?

Yes, but the two coverages serve different purposes. If you have Type 2 diabetes, your Part D plan likely already covers Ozempic or Mounjaro for blood sugar management. The Bridge program covers Wegovy and Zepbound specifically for weight loss. If you want to switch from a diabetes GLP-1 to a weight-loss GLP-1, or if you want weight loss coverage specifically, the Bridge is the pathway. Discuss with your doctor which approach is clinically appropriate.

What if my BMI drops below the threshold while I'm on the medication?

The eligibility criteria specify BMI at the time of initiating GLP-1 therapy. CMS has not indicated that you would lose coverage if your BMI drops below the qualifying threshold during the Bridge period — after all, weight loss is the intended outcome of the treatment. However, re-qualification may be required when transitioning to the BALANCE Model in January 2027.

Will my regular pharmacy accept Bridge program prescriptions?

CMS is releasing the full list of participating pharmacies in Spring 2026. Because the Bridge uses the same infrastructure as the LI NET program (administered by Humana), it will likely have broad pharmacy network coverage. Major chains such as CVS, Walgreens, and Walmart are expected to participate, but check the official list once it's published at cms.gov.

Can I use a telehealth provider for the prescription?

The Bridge program requires a prescription from a qualifying medical provider. CMS has not restricted this to in-person visits. Many Medicare beneficiaries already use telehealth for GLP-1 prescriptions through platforms listed on our provider rankings page. However, not all telehealth GLP-1 providers accept Medicare — check our rankings to filter by Medicare-compatible providers, or take the match quiz for a personalized recommendation.

Is there a limit on how many months I can use the Bridge?

The Bridge runs for six months (July through December 2026). You can fill prescriptions each month during that window. There is no indication of a lifetime limit within the program period. After December 31, 2026, coverage transitions to the BALANCE Model.

What about Medicare Advantage plans?

If you have a Medicare Advantage plan with prescription drug coverage (MA-PD), you are eligible for the Bridge program. The Bridge operates outside your MA-PD benefit structure, so it works the same way regardless of whether you have Original Medicare with a standalone Part D plan or a Medicare Advantage plan with built-in drug coverage.

Can I use an HSA or FSA to cover the $50 copay?

If you have a Health Savings Account (HSA), yes — the $50 copay is a qualifying medical expense. FSAs are less common among Medicare beneficiaries (you generally can't contribute to an HSA once enrolled in Medicare, but you can spend down an existing balance). The copay is also deductible as a medical expense on your tax return if your total medical expenses exceed 7.5% of your adjusted gross income.

How This Compares to Other Coverage Options

The Medicare GLP-1 Bridge offers the second-cheapest way to access brand-name GLP-1 medications in 2026. Here is how it stacks up against every major access pathway:

At $50/month, the Bridge is significantly cheaper than any self-pay option for brand-name medications. The only cheaper pathway is commercial insurance with manufacturer savings cards ($25/month), which isn't available to Medicare beneficiaries. If you've been paying out of pocket for a GLP-1 through a telehealth provider, the Bridge could save you $100-$300 per month while giving you access to the FDA-approved brand-name product.

Potential Challenges and What Could Go Wrong

While the Bridge program is genuinely good news for Medicare beneficiaries, there are several potential issues to be aware of:

• •Supply constraints: Adding millions of potential new patients to the GLP-1 supply chain could create shortages. Wegovy and Zepbound experienced significant supply issues in 2023-2024. Both Novo Nordisk and Eli Lilly have expanded manufacturing capacity, but the demand spike from Medicare coverage is unprecedented
• •Prior authorization delays: The centralized PA process through Humana is new infrastructure. Early months could see processing delays as the system ramps up. Starting your PA process early (the day the system opens) is advisable
• •Restrictive eligibility: The three-tier BMI criteria are more restrictive than standard FDA indications. Some people who would qualify for GLP-1s through commercial insurance may not meet the Bridge criteria. For example, someone with BMI 28 and hypertension on only one medication would not qualify under any tier
• •BALANCE Model uncertainty: The January 2027 transition to BALANCE requires your Part D plan to voluntarily participate. If few plans opt in, some beneficiaries could face a coverage gap. This is the biggest structural risk in the program
• •Six-month duration: GLP-1 medications require gradual dose titration over 4-5 months to reach maintenance doses. Starting in July means you may just be reaching full dose when the Bridge ends in December. Continuity of care depends on a smooth BALANCE transition

Who Should NOT Use the Medicare GLP-1 Bridge

The Bridge program is not appropriate for everyone. You should discuss alternatives with your doctor if any of the following apply:

• •You have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — both Wegovy and Zepbound carry FDA boxed warnings contraindicating use in these patients
• •You have a history of pancreatitis — GLP-1 medications carry a risk of pancreatitis and are generally not recommended if you have had it before
• •You already have effective GLP-1 coverage — if your Part D plan covers a GLP-1 for diabetes and you're already taking it, switching to the Bridge may not be necessary. Discuss with your doctor
• •Your BMI does not meet any of the three tiers — if you're below BMI 27 (or between 27 and 30 without qualifying cardiovascular conditions), you will not be eligible
• •You are unable to commit to lifestyle modifications — the Bridge requires the prescription to be in combination with structured nutrition and physical activity. This is not a medication-only program

The Bottom Line: This Is a Historic Opportunity

The Medicare GLP-1 Bridge represents the largest expansion of weight loss medication access in Medicare history. For the first time, the 68 million Americans on Medicare will have a structured, affordable pathway to the same GLP-1 medications that have been transforming weight management for younger, commercially insured patients since 2021.

At $50 per month, the Bridge program removes the single biggest barrier to GLP-1 access for seniors — cost. For context, the STEP 1 trial showed that semaglutide (Wegovy) produced an average of 14.9% body weight loss over 68 weeks, and the SURMOUNT-1 trial showed tirzepatide (Zepbound) produced up to 22.5% body weight loss over 72 weeks. For a 250-pound Medicare beneficiary, that could mean losing 37-56 pounds — with corresponding improvements in blood pressure, blood sugar, joint pain, sleep apnea, and cardiovascular risk.

The window is specific: July 1 through December 31, 2026. Six months. If you qualify, the preparation timeline above gives you a clear path to being ready on launch day. Start the conversation with your doctor now, get your documentation in order, and watch for CMS updates on the operational details expected this spring.

Not sure where to start? Our ranked provider comparison shows which GLP-1 telehealth platforms work with Medicare patients, and the match quiz can help you find the right fit based on your insurance, medication preference, and budget. You can also use the cost calculator to model your total costs under the Bridge program versus other options.